EP0959072A1 — Sulfonamide derivative and process for preparing the same
Assigned to Tanabe Pharma Corp · Expires 1999-11-24 · 26y expired
What this patent protects
Novel sulfonamide derivatives of the formula [I]: wherein Ring A and Ring B are substituted or unsubstituted monocyclic, bicyclic or tricyclic hydrocarbon, or substituted or unsubstituted heterocyclic group, Q is single bond, -O-, -S-, -SO-, -SO 2 - or -CH 2 -, Y is -O-, -S- or…
USPTO Abstract
Novel sulfonamide derivatives of the formula [I]: wherein Ring A and Ring B are substituted or unsubstituted monocyclic, bicyclic or tricyclic hydrocarbon, or substituted or unsubstituted heterocyclic group, Q is single bond, -O-, -S-, -SO-, -SO 2 - or -CH 2 -, Y is -O-, -S- or -NH-, Alk is lower alkylene or alkenylene, Z is -O- or -NH-, R is substituted or unsubstituted aromatic heterocyclic or aryl, R 1 is H, trifluoromethyl, substituted or unsubstituted amino, substituted or unsubstituted lower alkyl, alkenyl, alkynyl, substituted or unsubstituted lower alkylthio, or alkoxy, or substituted or unsubstituted heterocyclic or aryl, or pharmaceutically acceptable salts thereof, which are useful in the prophylaxis or treatment of disorders associated with endothelin activities such as hypertension, pulmonary hypertension, renal hypertension, Raynaud disease, bronchial asthma, gastric ulcer, chronic heart failure, etc.
Drugs covered by this patent
- Opsumit (MACITENTAN) · AstraZeneca
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.